Association between hTERT activation by HPV E6 proteins and oncogenic risk.

Expression of activated telomerase and subversion of the p16/pRb pathway is sufficient and essential for the in vitro immortalization of primary keratinocytes. Most cancers-including cervical carcinoma-over-express hTERT, the catalytic domain of the telomerase complex. Only a limited set of viruses within the Alphapapillomavirus genus are oncogenic. The viral functions responsible for this distinction are not well understood. The human papillomavirus type 16 E6 protein activates the hTERT promoter. We used a luciferase-based assay to test the ability of 29 viral types, representing all current species within the Alphapapillomavirus genus, to activate the hTERT promoter. We show that oncogenic types specifically activate the hTERT promoter, while non-oncogenic types do not. Statistical analysis supports the notion that activation of the hTERT promoter is uniquely associated with oncogenic types, independent of evolutionary relationships. This finding begins to shed light on the viral phenotypes correlated with oncogenic potential.

[1]  T. Veldman,et al.  Transcriptional Activation of the Telomerase hTERT Gene by Human Papillomavirus Type 16 E6 Oncoprotein , 2001, Journal of Virology.

[2]  S. Hsueh,et al.  Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial neoplasia lesions. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Kiyono,et al.  Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. , 2004, Genes & development.

[4]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[5]  A. Cheung,et al.  Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer. , 1999, European journal of cancer.

[6]  T. Veldman,et al.  Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. P. Anderson,et al.  Telomerase activation in cervical cancer. , 1997, The American journal of pathology.

[8]  R. Schlegel,et al.  The Human Papillomavirus Type 16 E6 and E7 Oncoproteins Dissociate Cellular Telomerase Activity from the Maintenance of Telomere Length* , 1997, The Journal of Biological Chemistry.

[9]  R. DeSalle,et al.  The carcinogenicity of human papillomavirus types reflects viral evolution. , 2005, Virology.

[10]  M. Yutsudo,et al.  Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. , 1999, Cancer research.

[11]  David Posada,et al.  MODELTEST: testing the model of DNA substitution , 1998, Bioinform..

[12]  John P. Huelsenbeck,et al.  MrBayes 3: Bayesian phylogenetic inference under mixed models , 2003, Bioinform..

[13]  C. Cerni,et al.  Telomeres, telomerase, and myc. An update. , 2000, Mutation research.

[14]  T. Iwasaka,et al.  Telomerase Activation in Cervical Neoplasia , 1998, Obstetrics and gynecology.

[15]  D. Galloway,et al.  Destabilization of the Retinoblastoma Tumor Suppressor by Human Papillomavirus Type 16 E7 Is Not Sufficient To Overcome Cell Cycle Arrest in Human Keratinocytes , 2001, Journal of Virology.

[16]  R. Burk,et al.  Evolution of human papillomavirus carcinogenicity. , 2010, Advances in virus research.

[17]  James C. Wilgenbusch,et al.  AWTY (are we there yet?): a system for graphical exploration of MCMC convergence in Bayesian phylogenetics , 2008, Bioinform..

[18]  D. Wazer,et al.  E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. , 1996, Cancer research.

[19]  A. Klingelhutz,et al.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses. , 2012, Virology.

[20]  P. Yaswen,et al.  Viral oncogenes accelerate conversion to immortality of cultured conditionally immortal human mammary epithelial cells , 1999, Oncogene.

[21]  K. Shroyer,et al.  Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix. , 2000, American journal of clinical pathology.

[22]  Claude Fauquet,et al.  Classification of papillomaviruses. , 2004, Virology.

[23]  Renxiang Chen,et al.  HPV E6 protein interacts physically and functionally with the cellular telomerase complex , 2009, Proceedings of the National Academy of Sciences.

[24]  D. McCance,et al.  Degradation of p53, Not Telomerase Activation, by E6 Is Required for Bypass of Crisis and Immortalization by Human Papillomavirus Type 16 E6/E7 , 2004, Journal of Virology.

[25]  T. Sugino,et al.  Telomerase activity in human gynaecological malignancies. , 1997, Journal of clinical pathology.

[26]  W. Hahn,et al.  Immortalization and transformation of primary human airway epithelial cells by gene transfer , 2002, Oncogene.

[27]  T. Kiyono,et al.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells , 1998, Nature.

[28]  humAn cArcinogens,et al.  iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns , 2012 .

[29]  J. McDougall,et al.  Telomerase activation by the E6 gene product of human papillomavirus type 16 , 1996, Nature.

[30]  Baojin Fu,et al.  The E6AP Ubiquitin Ligase Is Required for Transactivation of the hTERT Promoter by the Human Papillomavirus E6 Oncoprotein* , 2005, Journal of Biological Chemistry.

[31]  E. de Villiers,et al.  Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. , 2010, Virology.

[32]  A. Zetterberg,et al.  Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas , 2002, Genes, chromosomes & cancer.

[33]  K. Katoh,et al.  MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. , 2002, Nucleic acids research.

[34]  A. Klingelhutz,et al.  HPV16‐E6 associated hTERT promoter acetylation is E6AP dependent, increased in later passage cells and enhanced by loss of p300 , 2006, International journal of cancer.

[35]  O. Gascuel,et al.  SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. , 2010, Molecular biology and evolution.

[36]  D. Galloway,et al.  E Box-Dependent Activation of Telomerase by Human Papillomavirus Type 16 E6 Does Not Require Induction of c-myc , 2001, Journal of Virology.

[37]  R. Burk,et al.  Degradation of p53 by Human Alphapapillomavirus E6 Proteins Shows a Stronger Correlation with Phylogeny than Oncogenicity , 2010, PloS one.

[38]  L. Mariani,et al.  Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high‐risk human papillomavirus, virus persistence, or disease outcome in cervical cancer , 2006, Diagnostic cytopathology.

[39]  L. Laimins,et al.  Telomerase Activation by Human Papillomavirus Type 16 E6 Protein: Induction of Human Telomerase Reverse Transcriptase Expression through Myc and GC-Rich Sp1 Binding Sites , 2001, Journal of Virology.

[40]  A. Zuckerman,et al.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1995, IARC monographs on the evaluation of carcinogenic risks to humans.

[41]  Kurt Straif,et al.  A review of human carcinogens--Part F: chemical agents and related occupations. , 2009, The Lancet. Oncology.

[42]  M. Schiffman,et al.  Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline , 2009, Infectious Agents and Cancer.